Xi Lei et al., 2025-05-29: Lei et al. show fenbendazole kills both bulk cervical cancer cells and CD133+/CD44+ cervical cancer stem cells, the population associated with therapy resistance, and suppresses xenograft growth at 100 mg/kg.
FBZ dose-dependently inhibited proliferation, induced G2/M arrest, and triggered apoptosis in both CCCs and CCSCs.
Xi Lei et al., 2025-05-29: Lei et al. show fenbendazole kills both bulk cervical cancer cells and CD133+/CD44+ cervical cancer stem cells, the population associated with therapy resistance, and suppresses xenograft growth at 100 mg/kg. Study type: HeLa and C-33 A cell lines with isolated cancer stem cells, plus xenograft models. N: not stated in the abstract. Country: China (Jilin). Dose: 50 and 100 mg/kg in vivo; 100 mg/kg suppressed growth with 100% survival versus 40% for cisplatin and 0% untreated (full text). Funder: Department of Science and Technology of Jilin Province (20220204022YY). Declared conflicts: 'The authors declare no conflicts of interest.' Comparator: cisplatin and untreated controls. Study type: animal.
